Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–14 of 14 results
Advanced filters: Author: Katalin Karikó Clear advanced filters

  • Katalin Karikó describes the discovery that replacing uridine with pseudouridine renders RNA non-immunogenic. This paved the way for developing mRNA for protein replacement therapy and, surprisingly, also for mRNA-based vaccine development.

    • Katalin Karikó
    Research Highlights
    Nature Reviews Immunology
    Volume: 21, P: 619

  • Monoclonal antibodies are highly effective therapeutics that can be delivered as proteins or encoded DNA or mRNA. Here the authors develop lipid nanoparticle-formulated nucleoside-modified mRNA encoding an HIV-1 neutralizing antibody and see sustained and protective antibody levels in treated mice.

    • Norbert Pardi
    • Anthony J. Secreto
    • Drew Weissman
    ResearchOpen Access
    Nature Communications
    Volume: 8, P: 1-8

  • Dysfunction of the lymphatic system leads to secondary lymphedema and results in degradation of quality of life. Here, the authors show that delivery of nucleoside-modified Vascular Endothelial Growth Factor C (VEGFC) mRNA, encapsulated in lipid nanoparticles, induces organ-specific lymphatic growth and reverses experimental lymphedema.

    • Dániel Szőke
    • Gábor Kovács
    • Zoltán Jakus
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-18

  • The therapeutic potential ofin vitro-transcribed mRNA (IVT mRNA) extends from prophylactic and therapeutic vaccines to applications such as protein replacement and genome engineering. In this Review, the authors describe the recent developments in the IVT mRNA field, discuss the class-specific challenges with regards to translating IVT mRNA into a biopharmaceutical, and provide an overview of IVT mRNA drugs in development for different indications.

    • Ugur Sahin
    • Katalin Karikó
    • Özlem Türeci
    Reviews
    Nature Reviews Drug Discovery
    Volume: 13, P: 759-780

  • The antiangiogenic effect of siRNAs does not depend on the target of the siRNA, or on intraocular administration. Rather, the siRNAs activate TLR3, a cell surface receptor for long viral dsRNAs, and innate immunity.

    • Mark E. Kleinman
    • Kiyoshi Yamada
    • Jayakrishna Ambati
    Research
    Nature
    Volume: 452, P: 591-597

  • In geographic atrophy, a type of macular degeneration, retinal pigmented epithelium (RPE) cells die. This paper finds that DICER1, which processes miRNA precursors, is reduced in RPE from individuals with geographic atrophy. Cell death is not due to loss of miRNA processing, however; rather, the absence of DICER1 allows accumulation of pathological Alu repeat sequence RNAs. This work reveals a novel function of Dicer in degrading Alu RNAs.

    • Hiroki Kaneko
    • Sami Dridi
    • Jayakrishna Ambati
    Research
    Nature
    Volume: 471, P: 325-330

  • The highly conserved influenza virus hemagglutinin (HA) stalk represents a potential target for a broadly protective vaccine. Here, the authors show that immunization with nucleoside-modified mRNA encoding full-length HA formulated in lipid nanoparticles elicits HA stalk-specific antibodies and protects from heterosubtypic virus infection.

    • Norbert Pardi
    • Kaela Parkhouse
    • Drew Weissman
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-12

  • A single, low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA encoding the pre-membrane and envelope glycoproteins of Zika virus protects both mice and rhesus macaques against infection and elicits rapid and long-lasting neutralizing antibody responses.

    • Norbert Pardi
    • Michael J. Hogan
    • Drew Weissman
    Research
    Nature
    Volume: 543, P: 248-251

  • Bispecific antibodies that connect T cells with tumor cells can be delivered in the form of in vitro–transcribed pharmacologically optimized mRNA; when injected into mice, these mRNA-encoded antibodies reject large established tumors as efficiently as the corresponding recombinant antibody protein.

    • Christiane R Stadler
    • Hayat Bähr-Mahmud
    • Ugur Sahin
    Research
    Nature Medicine
    Volume: 23, P: 815-817